| Mark Daniel Lopez, MD | |
|
1120 15th St, Augusta, GA 30912-0004 | |
| (706) 721-4951 | |
| (706) 721-7941 |
| Full Name | Mark Daniel Lopez |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 31 Years |
| Location | 1120 15th St, Augusta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053420257 | NPI | - | NPPES |
| G49055 | Medicaid | SC | |
| 000875388A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0204X | Pediatrics - Pediatric Emergency Medicine | 049055 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Au Medical Center | Augusta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Au Medical Associates Emergency Medicine Billing Services, Llc | 3072823186 | 45 |
News Archive
Heart attack symptoms can be gradual or abrupt and both situations are a medical emergency. That's the main message of research published today in the European Journal of Cardiovascular Nursing, a journal of the European Society of Cardiology.
A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute in Sarasota.
PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).
Over 100 candidate vaccines are being explored as a means of ending the COVID-19 pandemic. Eight of these have already made it to clinical trials in humans, and another 94 are in the pre-clinical evaluation stage.
› Verified 8 days ago
| Entity Name | Au Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841230620 PECOS PAC ID: 9931013513 Enrollment ID: O20040107000188 |
News Archive
Heart attack symptoms can be gradual or abrupt and both situations are a medical emergency. That's the main message of research published today in the European Journal of Cardiovascular Nursing, a journal of the European Society of Cardiology.
A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute in Sarasota.
PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).
Over 100 candidate vaccines are being explored as a means of ending the COVID-19 pandemic. Eight of these have already made it to clinical trials in humans, and another 94 are in the pre-clinical evaluation stage.
› Verified 8 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
Heart attack symptoms can be gradual or abrupt and both situations are a medical emergency. That's the main message of research published today in the European Journal of Cardiovascular Nursing, a journal of the European Society of Cardiology.
A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute in Sarasota.
PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).
Over 100 candidate vaccines are being explored as a means of ending the COVID-19 pandemic. Eight of these have already made it to clinical trials in humans, and another 94 are in the pre-clinical evaluation stage.
› Verified 8 days ago
| Entity Name | Au Medical Associates Emergency Medicine Billing Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982089777 PECOS PAC ID: 3072823186 Enrollment ID: O20151102001458 |
News Archive
Heart attack symptoms can be gradual or abrupt and both situations are a medical emergency. That's the main message of research published today in the European Journal of Cardiovascular Nursing, a journal of the European Society of Cardiology.
A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute in Sarasota.
PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).
Over 100 candidate vaccines are being explored as a means of ending the COVID-19 pandemic. Eight of these have already made it to clinical trials in humans, and another 94 are in the pre-clinical evaluation stage.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Daniel Lopez, MD 1499 Walton Way, Ste 1400, Augusta, GA 30901-2602 Ph: (706) 828-6410 | Mark Daniel Lopez, MD 1120 15th St, Augusta, GA 30912-0004 Ph: (706) 721-4951 |
News Archive
Heart attack symptoms can be gradual or abrupt and both situations are a medical emergency. That's the main message of research published today in the European Journal of Cardiovascular Nursing, a journal of the European Society of Cardiology.
A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute in Sarasota.
PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).
Over 100 candidate vaccines are being explored as a means of ending the COVID-19 pandemic. Eight of these have already made it to clinical trials in humans, and another 94 are in the pre-clinical evaluation stage.
› Verified 8 days ago
Kenny Esho, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 574-850-2999 | |
Janelle Mcgill, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 706-721-8623 | |
Kristen Beeler, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 1446 Harper St, Augusta, GA 30912 Phone: 706-721-5437 | |
Lorna Evorie Bell, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 706-721-4951 Fax: 706-721-7941 | |
Dr. William Weston Iii, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 93 Bristlecone Ct., Augusta, GA 30909 Phone: 706-736-3704 | |
Dr. Amanda Chaffin, Pediatrics Medicare: Medicare Enrolled Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 706-721-9442 | |
Aaron W Hanna, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1245 Augusta West Pkwy, Augusta, GA 30909 Phone: 706-868-0389 Fax: 706-651-0729 |